About QSAM Biosciences
QSAM Biosciences is a company based in Palm Beach (United States) founded in 2004 was acquired by Telix Pharma in February 2024. The company has 4 employees as of December 31, 2021. QSAM Biosciences operates in a competitive market with competitors including SpringWorks Therapeutics, Sana Biotechnology, Janux Therapeutics, GigaGen and Kronos Bio, among others.
- Headquarter Palm Beach, United States
- Employees 4 as on 31 Dec, 2021
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Q2earth Inc.
-
Annual Revenue
Not available
-
Net Profit
-$4.39 M (USD)20as on Dec 31, 2023
-
EBITDA
-$3.94 M (USD)28as on Dec 31, 2023
-
Latest Funding Round
$2.5 M (USD), Post-IPO
Jan 28, 2021
-
Investors
Telix Pharmaceuticals
& 1 more
-
Employee Count
4
as on Dec 31, 2021
-
Acquired by
Telix Pharma
(Feb 08, 2024)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of QSAM Biosciences
Investors in QSAM Biosciences
QSAM Biosciences has secured backing from 2 investors, including venture fund and institutional investors. Prominent investors backing the company include Telix Pharmaceuticals and Checkmate Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Checkmate Capital is backed by family office for private equity.
|
Locked | Locked | Locked | |
|
Theranostic radiopharmaceuticals are developed for cancer imaging and therapy.
|
Locked | Locked | Locked |
Investor details for QSAM Biosciences
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by QSAM Biosciences
Investment portfolio details for QSAM Biosciences
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - QSAM Biosciences
Detailed financials for QSAM Biosciences
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Qsam Biosciences Comparisons
Peer comparison for QSAM Biosciences
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of QSAM Biosciences
QSAM Biosciences operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as SpringWorks Therapeutics, Sana Biotechnology, Janux Therapeutics, GigaGen and Kronos Bio, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Small molecule therapeutics are developed for cancer and rare diseases.
|
|
| Locked | Locked | Locked |
Genetically engineered cell therapies are developed for multiple disorders.
|
|
| Locked | Locked | Locked |
Immunotherapeutics for cancer treatment are developed to target solid tumors.
|
|
| Locked | Locked | Locked |
T-cell and antibody-based therapeutics are developed via single-cell sequencing platforms.
|
|
| Locked | Locked | Locked |
Small molecule therapeutics for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Chimeric antigen receptor macrophages are developed for cancer treatment.
|
Detailed competitors of QSAM Biosciences
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Qsam Biosciences
Complete news archive for QSAM Biosciences
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about QSAM Biosciences
QSAM Biosciences was founded in 2004 and raised its 1st funding round 13 years after it was founded.
QSAM Biosciences is headquartered in Palm Beach, United States. It is registered at Palm Beach, Florida, United States.
Kevin Bolin is the current CEO of QSAM Biosciences.
As of Dec 31, 2021, the latest employee count at QSAM Biosciences is 4.
Nuclear medicines for treating bone cancer and bone marrow ablation are developed by QSAM Biosciences, founded in 2004 and based in Palm Beach, United States. Operations focus on radiopharmaceuticals like Samarium-153 DOTMP, known as CycloSam, which emits beta and gamma radiation to target cancer cells. Applications include osteosarcoma, metastatic bone cancers, immune and blood diseases, and sickle cell conditions within the biotechnology sector.
QSAM Biosciences's top competitors include SpringWorks Therapeutics, Janux Therapeutics and Kronos Bio.
QSAM Biosciences has 2 investors. Key investors include Telix Pharmaceuticals, and Checkmate Capital.